New Findings From REPLACE Study Support Potential of Natpara to Treat Adult Hypoparathyroidism

NPS Pharmaceuticals announced that new findings from the double-blind, placebo-controlled Phase III REPLACE study of Natpara (recombinant human parathyroid hormone (rhPTH [1-84])) support the drug’s therapeutic potential as the first parathyroid hormone replacement therapy for adults with hypoparathyroidism.
4-Traders